CNTN4: A Non-Coding RNA Molecule Involved in Axonal Connections and Neurocircuit Development

Target Name: CNTN4

NCBI ID: G152330

CNTN4

CNTN4: A Non-Coding RNA Molecule Involved in Axonal Connections and Neurocircuit Development

CNTN4 is a non-coding RNA molecule that is expressed in a variety of tissues, including brain, heart, and muscle. It has been identified as an axonal-associated cell adhesion molecule (AACM), which means that it is involved in the formation and maintenance of axonal connections in the nervous system. While the exact function of CNTN4 is not yet fully understood, it is clear that it plays an important role in the development and maintenance of neural circuits.

Drug Target Potential

The potential drug target for CNTN4 is based on its role as an AACM. Drugs that target CNTN4 have the potential to modulate the strength and pattern of neural connections, which could lead to improved cognitive function and treatment of neurological disorders.

One approach to targeting CNTN4 is to use small molecules that can modulate the activity of CNTN4 enzymes. These molecules could act on CNTN4 to either activate or inhibit its activity, leading to changes in the levels of CNTN4 in the cell. One example of a small molecule that has been shown to interact with CNTN4 is the drug tirasirasuinden, which is a potent inhibitor of CNTN4.

Another approach to targeting CNTN4 is to use antibodies that recognize and label CNTN4. These antibodies could be used to either activate or inhibit CNTN4 activity, depending on the level of CNTN4 in the cell. One example of an antibody that has been shown to interact with CNTN4 is the monoclonal antibody (mAb) 5E10, which recognizes a specific epitope on the CNTN4 protein.

CNTN4 as a Biomarker

CNTN4 has also been identified as a potential biomarker for certain neurological disorders. For example, high levels of CNTN4 have been observed in the brains of individuals with Alzheimer's disease, which is thought to be caused by the accumulation of beta-amyloid plaques. This suggests that CNTN4 may be a useful biomarker for the diagnosis and treatment of Alzheimer's disease.

In addition, CNTN4 has also been shown to be elevated in the brains of individuals with Parkinson's disease, which is characterized by the loss of dopamine-producing neurons in the brain. This suggests that CNTN4 may be a useful biomarker for the diagnosis and treatment of Parkinson's disease.

Conclusion

CNTN4 is a non-coding RNA molecule that is involved in the formation and maintenance of axonal connections in the nervous system. While the exact function of CNTN4 is not yet fully understood, it is clear that it plays an important role in the development and maintenance of neural circuits. The potential drug target for CNTN4 is based on its role as an AACM, and the use of small molecules and antibodies to modulate its activity. CNTN4 has also been identified as a potential biomarker for certain neurological disorders, which could be useful for the diagnosis and treatment of these disorders. Further research is needed to fully understand the role of CNTN4 in the nervous system and its potential as a drug target.

Protein Name: Contactin 4

Functions: Contactins mediate cell surface interactions during nervous system development. Has some neurite outgrowth-promoting activity. May be involved in synaptogenesis

The "CNTN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNTN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets